Management strategies for gastroesophageal reflux disease

被引:13
作者
Bak, YT [1 ]
机构
[1] Korea Univ, Coll Med, Dept Internal Med, Seoul 136701, South Korea
关键词
gastroesophageal reflux disease; management strategy; proton pump inhibitor; maintenance therapy; on-demand therapy;
D O I
10.1111/j.1440-1746.2004.03587.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
In the treatment of gastroesophageal reflux disease (GERD), the most effective treatment option is the use of proton pump inhibitor (PPI), which minimizes the effect of gastric acid on the distal esophagus. Both the step-up and step-down treatment strategies have advantages and disadvantages. Most physicians would like to choose the step-down therapy rather than the step-up therapy. The 'No-step' PPI therapy (i.e. continuous PPI therapy) is another relevant option. After an initial remission, long-term PPI therapy is an appropriate form of maintenance therapy in many patients. As a treatment plan for non-erosive reflux disease, a standard dose of PPI for 4-8 weeks followed by either the step-down strategy or the on-demand treatment strategy is acceptable. When treating erosive esophagitis, PPI is better than H-2 receptor blockers in healing mucosal breaks and relieving symptoms. Long-term maintenance PPI therapy is reported to be very effective in maintaining the remission of reflux esophagitis for up to 5 years. On-demand PPI is also another good option for a maintenance therapy in erosive esophagitis. In Barrett's esophagus, symptoms seem to be well-controlled with PPIs. Unfortunately, however, PPIs have no effect on the shortening of Barrett's esophagus or in preventing the progression to dysplasia and adenocarcinoma. In summary, after reviewing existing guidelines a rather simple guideline on the management of GERD is suggested - PPI should be given for 4-8 weeks followed by either on-demand or maintenance PPI therapy according to the clinical severity. (C) 2004 Blackwell Publishing Asia Pty Ltd.
引用
收藏
页码:S49 / S53
页数:5
相关论文
共 27 条
[1]
Intermittent and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease [J].
Bardhan, KD .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (03) :S40-S48
[2]
Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients [J].
Bytzer, P .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (03) :S31-S39
[3]
Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis [J].
Chiba, N ;
DeGara, CJ ;
Wilkinson, JM ;
Hunt, RH .
GASTROENTEROLOGY, 1997, 112 (06) :1798-1810
[4]
Management of gastro-oesophageal reflux disease in general practice [J].
Deng, J ;
Jones, R ;
Kahrilas, P ;
Talley, NJ .
BRITISH MEDICAL JOURNAL, 2001, 322 (7282) :344-347
[5]
An evidence-based appraisal of reflux disease management - the Genval workshop report [J].
Dent, J ;
Brun, J ;
Fendrick, AM ;
Fennerty, MB ;
Janssens, J ;
Kahrilas, PJ ;
Lauritsen, K ;
Reynolds, JC ;
Shaw, M ;
Talley, NJ .
GUT, 1999, 44 :S1-S16
[6]
OMEPRAZOLE V RANITIDINE FOR PREVENTION OF RELAPSE IN REFLUX ESOPHAGITIS - A CONTROLLED DOUBLE-BLIND TRIAL OF THEIR EFFICACY AND SAFETY [J].
DENT, J ;
YEOMANS, ND ;
MACKINNON, M ;
REED, W ;
NARIELVALA, FM ;
HETZEL, DJ ;
SOLCIA, E ;
SHEARMAN, DJC .
GUT, 1994, 35 (05) :590-598
[7]
DeVault KR, 1999, AM J GASTROENTEROL, V94, P1434
[8]
Empirical trials in treatment of gastroesophageal reflux disease [J].
Fass, R .
DIGESTIVE DISEASES, 2000, 18 (01) :20-26
[9]
Fass R, 2002, AM J GASTROENTEROL, V97, P1901
[10]
Report of the Asia-Pacific consensus on the management of gastroesophageal reflux disease [J].
Fock, KM ;
Talley, N ;
Hunt, R ;
Fass, R ;
Nandurkar, S ;
Lam, SK ;
Goh, KL ;
Sollano, J .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2004, 19 (04) :357-367